Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Oct;6(10):551-9.
doi: 10.1038/nrneurol.2010.130. Epub 2010 Sep 14.

How does diabetes accelerate Alzheimer disease pathology?

Affiliations
Review

How does diabetes accelerate Alzheimer disease pathology?

Catrina Sims-Robinson et al. Nat Rev Neurol. 2010 Oct.

Abstract

Diabetes and Alzheimer disease (AD)-two age-related diseases-are both increasing in prevalence, and numerous studies have demonstrated that patients with diabetes have an increased risk of developing AD compared with healthy individuals. The underlying biological mechanisms that link the development of diabetes with AD are not fully understood. Abnormal protein processing, abnormalities in insulin signaling, dysregulated glucose metabolism, oxidative stress, the formation of advanced glycation end products, and the activation of inflammatory pathways are features common to both diseases. Hypercholesterolemia is another factor that has received attention, owing to its potential association with diabetes and AD. This Review summarizes the mechanistic pathways that might link diabetes and AD. An understanding of this complex interaction is necessary for the development of novel drug therapies and lifestyle guidelines aimed at the treatment and/or prevention of these diseases.

PubMed Disclaimer

Conflict of interest statement

Competing Interests

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Altered insulin signaling in diabetes might contribute to Alzheimer disease pathophysiology. In type 1 diabetes, insulin deficiency attenuates LTP and might lead to deficits in spatial learning and memory. In type 2 diabetes, insulin resistance leads to both Aβ plaque formation and tau hyperphosphorylation. During hyperinsulinemia, insulin and Aβ compete for insulin-degrading enzyme, leading to Aβ accumulation and plaque formation. A decrease in insulin receptor signaling leads to inhibition of Akt and dephosphorylation (activation) of GSK-3β, and results in tau hyperphosphorylation. Abbreviations: Aβ, amyloid-β; GSK-3β, glycogen synthase kinase 3β; LTP, long-term potentiation; P, phosphate.
Figure 2
Figure 2
Pathological mechanisms associated with diabetes might cause AD. Mitochondrial dysfunction, oxidative stress and dysregulated calcium homeostasis are all associated with diabetes and might be contributory factors to the development of AD. Glucose auto-oxidation can lead to AGE formation and, as a result, oxidative stress, which is associated with mitochondrial dysfunction. Oxidative stress combined with an increase in intracellular calcium result in a feedforward cycle of continued mitochondrial damage that can cause neuronal death and, hence contribute to AD pathology. Abbreviations: AD, Alzheimer disease; AGE, advanced glycation end product; ROS, reactive oxygen species.

References

    1. Brands AM, Biessels GJ, de Haan EH, Kappelle LJ, Kessels RP. The effects of type 1 diabetes on cognitive performance: a meta-analysis. Diabetes Care. 2005;28:726–735. - PubMed
    1. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006;5:64–74. - PubMed
    1. Janson J, et al. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes. 2004;53:474–481. - PubMed
    1. Li L, Holscher C. Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res Rev. 2007;56:384–402. - PubMed
    1. Awad N, Gagnon M, Messier C. The relationship between impaired glucose tolerance, type 2 diabetes, and cognitive function. J Clin Exp Neuropsychol. 2004;26:1044–1080. - PubMed

Publication types

MeSH terms